Molecular Imaging

Molecular imaging (also called nuclear medicine or nuclear imaging) can image the function of cells inside the body at the molecular level. This includes the imaging modalities of positron emission computed tomography (PET) and single photon emission computed tomography (SPECT) imaging. How does PET and SPECT imaging work? Small amounts of radioactive material (radiopharmaceuticals) injected into a patient. These can use sugars or chemical traits to bond to specific cells. The radioactive material is taken up by cells that consume the sugars. The radiation emitted from inside the body is detected by photon detectors outside the body. Computers take the data to assemble images of the radiation emissions. Nuclear images may appear fuzzy or ghostly rather than the sharper resolution from MRI and CT. But, it provides metabolic information at a cellular level, showing if there are defects in the function of the heart, areas of very high metabolic activity associated with cancer cells, or areas of inflammation, data not available from other modalities. These noninvasive imaging exams are used to diagnose cancer, heart disease, Alzheimer’s and Parkinson’s disease, bone disorders and other disorders.

FDA approves expanded use of PET imaging agent
The product's updated indications include quantification and long-term monitoring of amyloid plaques on imaging.
'Powerful' new PET agent improves the diagnosis of triple-negative breast cancer
The agent “exhibits powerful tumor delineation” in challenging cases of determining cancer subtypes, and could potentially lead to more personalized, effective treatment strategies.
Industry partnership set to advance research on theranostics
The deal will create a Therapy Command Center to support the study and use of theranostics across Massachusetts General Hospital and its affiliated centers in bordering states.
SNMMI unveils its 2025 Image of the Year
The designation was awarded to a research team from China, who analyzed the efficacy of a novel radiotracer developed to target expression of the PD-L1 protein in suspected head and neck cancers.
3 industry partnerships, 1 clinical aim: Enriching the global supply chain of medical isotopes
Nuclear medicine operations may soon enjoy steadier flows of certain in-demand radioisotopes. If so, much credit will go to companies that had the strategic sense to collaborate with each other.

USP postpones new chapters on safety standards for radiopharmaceuticals

Three chapters published in June by The United States Pharmacopeial Convention (USP) are under appeal and postponed "until further notice."

FDG-PET/CT radiomic features improves lung cancer care

Integrating 18FDG-PET/CT radiomic tumor and bone marrow features can help predict outcomes in patients with non-small cell lung cancer, according to a Sept. 17 study published in Radiology.

ANSTO confirms another shutdown at Mo-99 facility

The Australian Nuclear Science and Technology Organization (ANSTO) confirmed it has shut down its Lucas Heights nuclear medicine facility following a “mechanical fault,” The Guardian reported. The shutdown puts an added strain on Australia’s already short supply of molybdenum-99 (Mo-99).

ASNC publishes new amyloidosis imaging guidelines

“We anticipate that these expert multisocietal consensus recommendations on multimodality imaging in cardiac amyloidosis will standardize the diagnosis and improve the management of this highly morbid and underdiagnosed disease," wrote authors of the new guidelines published in the Journal of Nuclear Cardiology.

Nuclear medicine, cardio groups reject proposed myocardial PET cuts

Multiple nuclear medicine and cardiology groups are working to oppose potential cuts to myocardial PET scans that were made possible by the CMS 2020 Medicare Physician Fee Schedule (MPFS) proposed rule, according to a joint statement.

Industry groups oppose proposed myocardial PET cuts

When CMS released the 2020 Medicare Physician Fee Schedule (MPFS) proposed rule, it included revisions that could lead to technical component payment reductions of up to 80% for certain services related to myocardial PET scans.

Ga-PSMA-11 PET/CT adds value to prostate cancer management

Using [68Ga]Ga-PSMA-11 PET/CT to monitor treatment response in prostate cancer patients can offer important lesion-based insights over prostate-specific membrane antigen (PSMA)-based monitoring, according to a new study published in EJNMMI Research.

DOE hands out final cooperative agreement for Mo-99 production

The Department of Energy (DOE)’s National Nuclear Security Administration has issued a fourth, and final, cooperative agreement to Corvallis, Oregon-based Northwest Medical Isotopes, LLC.

Molecular Imaging

FDA approves expanded use of PET imaging agent

'Powerful' new PET agent improves the diagnosis of triple-negative breast cancer

Industry partnership set to advance research on theranostics

SNMMI unveils its 2025 Image of the Year

3 industry partnerships, 1 clinical aim: Enriching the global supply chain of medical isotopes